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The study involves cross-sectional analyses of 44,957 veterans and non-veterans
enrolled in Medicare. Merged Medicare claims for fee-for service enrollees and
survey data from multiple years of the Medicare Current Beneficiary Survey from
2001 through 2005. ACSH for thirteen conditions were identified using inpatient
Medicare claims and an algorithm developed by the Agency for Healthcare Quality,
which uses International Classification of Diseases, 9th edition codes. Dual use was
defined as having inpatient or outpatient visits to the VHA and consisted of pre-
dominant-VHA use and some VHA use. Unadjusted group differences in any ACSH
were tested using chi-square tests. Logistic regressions were used to analyze the
association between dual VHA use and ACSH after controlling for demographic,
socio-economic, health status, mental illness, smoking and obesity. All analyses
accounted for the complex design of the survey. RESULTS: The three most com-
mon ACSH were congestive heart failure, bacterial pneumonia, and chronic ob-
structive pulmonary disease. Among inpatient users, 10.1% had ASCH for acute
conditions and 15.8% for chronic conditions. Among all survey respondents, 5%
had any ACSH; the rates were 4.9% for VHA users and 3.7% for veterans with some
VHA use. In bivariate and multivariate analyses, dual use was not significantly
associated with any ACSH. CONCLUSIONS: In a representative sample of Medicare
beneficiaries, ACSHwere prevalent. Despite poor health status, dual VHA/Medicare
use was not associated with increased ACSH rates perhaps due to the provision of
good primary care in the VHA system.
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OBJECTIVES: Adolescence and young adulthood are an important transitional pe-
riod during which morbidity and mortality often arise from individual’s behaviors
such as alcohol and drug use, suicide, and poisonings. Self-report survey data
regarding health behaviors are readily available, however little data from objective
sources has been reported and minimal study of health care utilization, particu-
larly hospital utilization, related to these behaviors has been conducted. This study
examines the patterns and characteristics of individuals admitted to the hospital
for these conditions.METHODS: The data for this investigation came from the 2007
National Hospital Discharge Survey (NHDS). Records for all individuals who had an
age in the range of 10-24 years and were discharged from the hospital with any
recorded diagnosis of alcohol or drug abuse or dependence, suicide, or poisonings
were abstracted. National estimates were calculated utilizing the weighted num-
ber of discharges and the U.S. Census Bureau population data for this age group.
Rao-Scott Chi square tests were performed to evaluate differences between groups
and all significance tests were two-sided using p0.05 as the level of statistical
significance. RESULTS: National estimates for hospital discharges per 1,000 10-24
year olds are 54.2 for alcohol/drug use, 3.3 for suicide, and 9.8 for poisoning. Sea-
sonal trends in alcohol/drug and suicide discharges were observed, as were re-
gional differences with more than twice as many alcohol/drug-related discharges
in the South. Over 42% of all care related to these diagnoses is expected to be paid
for by public health insurance programs. Self-pay is also high for these conditions
(16.1%). CONCLUSIONS: A significant porition of inpatient hospital care for adoles-
cents and young adults is attributable to alcohol/drug use, suicide, and poisonings.
These data have implications for primary intervention programs and suggest the
need for further investigation of the associated health care costs related to these
conditions.
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OBJECTIVES: Electronic-medical-record (EMR) systems have the potential for im-
proving the quality of preventive healthcare forwomen, by reminding patients and
physicians to obtain appropriate screenings and vaccinations, and decrease
health-care costs significantly by preventing emergency-department visits and
hospitalizations. The objective was to study the effect of EMR-system sophistica-
tion on women’s healthcare in physician offices. METHODS: The National Ambu-
latory Medical Care Survey (NAMCS), a cross-sectional database of physicians’ of-
fice-based visits was analyzed. Based on several of the NAMCS questions, EMR-
systems were classified into nonexistent, minimal, basic, and fully functional
systems according to their set of specific functions. Visits were selected provided
that (1) they were made by a woman  18 years old and (2) the visit was not for a
chronic or acute illness as identified by the visit’s ICD-9 code. Preventive health-
care provision included screenings (mammography and bone-mineral-density im-
aging); exams (breast and pelvic); tests (PAP tests and tests for chlamydia, choles-
terol, and blood pressure); and vaccinations. Estimated frequencies of preventive
health services ordered or completed by the physician were for the four levels of
EMR-system sophistication. RESULTS: In 2007-08, 341,729 physicians ordered or
provided 2.56, 1.31, 1.97, and 1.82million preventive healthcare exams, screenings,
tests, and vaccinations for women aged 18-39, 40-49, 50-64, and 65, respectively.
The ratios of number of preventive women’s healthcare measures to number of
visits bywomen, for practiceswith no EMRwere the lowest (1.12, 1.21, 1.25 and 0.28
for age-groups 18-39, 40-49, 50-64, and 65, respectively). Whereas, practices with
fully-functional EMR systems had the highest ratios, (1.5, 1.54 and 0.48 for age-
groups 18-39, 50-64 and65, respectively), except for the 40-49 age group, forwhich
minimal-EMR-system practices had the highest ratio of 1.61. CONCLUSIONS: Evi-
dence suggests that the more sophisticated the EMR system, the greater the inten-
sity of preventive healthcare service provided to women.
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OBJECTIVES: Assess real world treatment patterns, health care utilization, and
costs of HMB patients. METHODS: Data were administrative claims from a large
national US health plan. Female plan enrollees aged 18-49 with at least 2 claims of
HMB (ICD-9-CM 626.2, 627.0) within 180 days during 01-01-04 to 02-29-08 were
included; index date was initial HMB claim. Continuous enrollment required 6mos
pre-index and 18mos post-index. Patientswere classified as idiopathic HMBunless
underlying conditions associated with HMB occurred in pre-index or 60 days post-
index date. All variables were analyzed descriptively. Multivariate analyses were
conducted to evaluate the factors associated with follow-up HMB-related costs.
RESULTS: Mean [SD] age of the study population (N21,239) was 39.5 [6.8]; mean
[SD] comorbidity score was 0.14 [0.42]. Of the 21,239 women, 57.6% had 1 treatment
episode, 15.7% had 2 or more, and 26.6% had no treatment during the post-index.
15,582 patients received treatment, the distribution of initial treatment was 36.4%
received medication (oral contraceptive [OC], non-OC, or oral medroxyprogester-
one acetate [MPA]), 50.8% had endometrial ablation [EA], and 12.6% underwent
hysterectomy. Mean [SD] HMB-related costs of single episode paths were: hyster-
ectomy $8,656.84 [$5,453.34]), EA $4,579.63 [$3,509.16], and no treatment $616.23
[$946.73]. On average follow-up HMB-related costs are expected to be 9.67 times
greater for womenwithmultiple episodes and 6.33 times greater for single episode
(ref. group: no treatment). Age, Charlson comorbidity score, geographical region
were also associated with higher total follow-up HMB-related costs whereas base-
line OC use and pregnancy during the follow-up lowered costs. CONCLUSIONS:
HMB has significant clinical and economic impact. Over 1/4 of patients did not
receive treatment. Prevalence of surgical procedures was high among those
treated, often constituting first-line treatment. Surgical procedures and multiple
treatment episodes were associated with higher HMB-related costs.
Individual’s Health – Research on Methods
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OBJECTIVES: Patients with unmet expectations for the time required to experience
improvement (or sustained improvement) with treatment may prematurely dis-
continue otherwise effective treatment. We assessed median time to successful
sexual intercourse (SSI) with sildenafil and placebo. METHODS: Successful sexual
intercourse was assessed in an 8-week, double-blind, placebo-controlled trial of
sildenafil treatment in men with erectile dysfunction. SSI for each episode of sex-
ual activity was defined by patient report and by two events: 1) the subject at-
tempted sexual intercourse and 2) the subject had an erection lasting long enough
for successful intercourse. Median time to SSI was calculated for two types of
events: 1) time to the first SSI (transient event) and 2) stable SSI (initial improve-
ment sustained for the remainder of the double-blind 56-day study, defined as at
least 50% of sexual intercourses being successful until the end of the study). Log-
rank tests compared time-to-event curves between treatment groups.RESULTS:Of
288 men enrolled, 95 received placebo, 99 received sildenafil 100 mg, and 94 re-
ceived sildenafil 50 mg. Median time from the start of the study to achieve initial
SSI was 3 days for each group of sildenafil-treated patients (50 mg and 100 mg),
compared with 13 days for placebo-treated patients (P0.001). (Note that not ev-
eryone attempted sexual intercourse on the first day of treatment.) Median time to
achieve stable (sustained) SSI was 5 days (50 mg) and 3 days (100 mg) for sildenafil-
treated patients versus 55 days for placebo-treated patients (P0.001).
CONCLUSIONS: This novel application of time-to-event analysis provides useful
timeframes for when patients can expect to see initial and then stable improve-
ments with sildenafil treatment. Median times to initial SSI and sustained SSI were
significantly shorter for sildenafil-treated vs placebo-treated men.
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OBJECTIVES: Effective treatment of bleedings in hemophiliac patients is important
for limiting costs associated with bleedings and for improving health outcomes.
Two health outcomes of interest is the time from treatment initiation to bleeding
resolution and the probability of developing re-bleedings. The objective of this
study was to develop a methodology with NBF instead of the ICER for estimating
the health economic benefits of a novel treatment with certain characteristics
compared to rFVIIa and to identify the major determinants of the net monetary
benefit of the novel treatment. METHODS: Data from a medical chart review on
hemophilia inhibitor patients in Turkey were used to identify predictors of the
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amount of rFVIIa used to achieve haemostasis. A Generalized Linear Regression
Model was used to derive the potential cost-offsets of a novel treatment. The net
monetary benefit per bleeding treated of the novel treatment compared to rFVIIa
was estimated using a variety of assumptions on the efficacy of the novel treat-
ment as well as on the valuation of the health benefits. RESULTS: Assuming a
reduction in time to bleeding resolution by 25%, a novel treatment saved €339 per
bleeding compared to rFVIIa. Including the value of the health benefits, whichwere
estimated to €51, the net monetary benefit of the novel treatment was €390 per
bleeding. The results were sensitive to assumptions around the efficacy of the new
treatment but also around the valuation of health benefits.CONCLUSIONS:Anovel
treatment which reduces time to bleeding resolution would entail important
health economic benefits, both in terms of health care cost-offsets and health
benefits. One limitation of cost-effectiveness analyses in hemophilia is the uncer-
tainty around the valuation of short term health benefits.
PIH43
METHODOLOGY TO IDENTIFY IN-VITRO FERTILIZATION PATIENTS USING A
NATIONAL MANAGED CARE DATABASE
Kozma C1, Fincher C2, Hubbard J3, Meletiche DM4
1Independent Research Consultant/Adjunct Professor, University of South Carolina, St. Helena
Island, SC, USA, 2EMD Serono, Inc., Ann Arbor, MI, USA, 3EMD Serono, Inc., San Jose, CA, USA,
4EMD Serono, Inc., Rockland, MA, USA
BACKGROUND:Themajority of analyses of outcomes related to fertility treatments
are conducted in datasets from fertility centers. To date there has been no estab-
lished methodology for identifying fertility protocols in payer databases.
OBJECTIVES: To identify a methodology for identifying fertility protocols in a na-
tional administrative claims database. METHODS: This retrospective descriptive
study used PharmMetrics, a national managed care dataset. Patients with at least
one prescription for a gonadotropin-releasing hormone agonist (GnRHAg) or an-
tagonist (GnRHAnt) between January 1, 1999 andMay 31, 2009 were selected. Drugs
billed with a National Drug Code were included and were identified using generic
product identifiers. Index date was set as the first pharmacy claim date for a Gn-
RHAg or GnRHAnt. Patients were excluded if no prescription record for FSH existed
in the 7 days pre-index through 60 days post-index and HCG in the 60 day post-
index period. Patients must be eligible for services for 12 months before and after
the index date, which established continuous eligibility for services. Longer eligi-
bility allows assessment of outcomes such as birth rates. The final sample con-
sisted of patientswith an embryo transfer codewithin 60 days of index. Outcome of
delivery codes served as indicators for live birth if they occurredwithin 294 days (42
weeks) after transfer date. RESULTS: Inclusion and exclusion criteria were ap-
plied to patients that had at least one prescription for GnRHAnt or GnRHAg,
resulting in some attrition of sample (880 patients with IVF). The 2-year contin-
uous eligibility requirement accounted for the largest number of patients
removed. CONCLUSIONS:Administrative claims data provide a large sample of IVF
patients, but are limited in some analyses due to a lack clinical details. The pro-
posedmethodology was able to successfully identify IVF treatment cycles and link
these to delivery outcomes for treated patients under real-world conditions.
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OBJECTIVES: Individual domains of multidomain patient-reported outcome in-
struments typically are analyzed independently, without considering inherent de-
pendency of component domains. This report presents an underused modeling
approach that accounts for correlations across time (longitudinal) and correlations
across domains of a multidomain instrument in one integrated model.METHODS:
International Index of Erectile Function (IIEF) data from a double-blind placebo-
controlled trial of fixed-dose sildenafil (50 or 100 mg) in 288 men with erectile
dysfunctionwere used. Standardmethodologywas used for the individual-domain
longitudinal model. This model was then expanded to account for relationships
among domains for the multidomain longitudinal model, performing modeling of
treatment effects on all domains simultaneously. Covariance was constructed by
taking the Kronecker product of an unstructured covariance matrix across do-
mains (modeling covariance across the domains) with an unstructured covariance
matrix across time (modeling covariance across time). Analyses were performed
with Proc Mixed using SAS v9.2. RESULTS: The model was constructed and fitted,
which integrated all IIEF domains simulataneously into one unified multidomain
longitudinal model. Treatment effects for all 5 IIEF domain scores calculated using
individual ormultidomainmodelingwere similar, reflecting the robust application
of IIEF data in this study. CONCLUSIONS: Modeling correlation structure simulta-
neously across domains of amultidomain instrument, as well as across time,more
rigorously addresses the interrelationship between domains and potentially pres-
ents a more accurate estimation of efficacy and statistical inferences. Additional
work with simulations and more empirical evidence are needed to better under-
stand the multidomain longitudinal model.
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OBJECTIVES: Efficiency in health systems is often a matter of concern and differ-
ences on the expected productivity of a given procedure might lead to inefficient
variations in the performance of such interventions. Health economics literature
has extensively revisited the topic of variations in health care using multivariate
models to predict variation across geographic regions. The clustering effect of fa-
cilities (as a functional unit), however. has not been described before. This analysis
examines the extent to which facilities explain geographic variation in health care.
METHODS: A set of individual data on all births from a Contributory-Regimen
insurer in Colombia was assessed. We performed a multilevel logistic regression
model, taking hospitals as the clustering variable. In addition, we included an
alternative variance decomposition specification to estimate the attributable effect
of geographic region on the variability across hospitals. We used a set of variables
includingmother education and income, physician fees, and complications during
pregnancy to control for in this analysis. RESULTS:Our results reveal that hospitals
account for 20% of variation on the probability of performing cesarean sections.
Geographic area only explains one-third of the variance attributable to the hospi-
tal. In addition, physician fees (0.077; SE 0.023), mother’s income (0.070; SE 0.014)
and superior education in mothers (0.299; SE 0.107). This supports the effect of
mother and physician preferences on variations. CONCLUSIONS: This paper con-
tributes to previous research by using amultilevel model approach and by defining
hospitals as cluster. We found a strong effect of hospitals on determining varia-
tions. In addition, we found how supply-side factors such as physician fees and
demand-side factors (proxies for preferences) such as mother’s education and in-
come are affecting variations across hospitals and regions. The effect of facility as
well as individual-level variables should be taken into account when researching
on variations in health care.
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OBJECTIVES: The linguistic validation and cognitive debriefing of PROs are now
well documented and routinely usedwithin the pharmaceutical industry to ensure
that the translated instruments are conceptually equivalent to their sources. In-
creasingly, new adjustments are being developed to further customize these pro-
cesses according to the special needs of the instrument and target culture. This
paper seeks to enumerate the challenges faced when debriefing questionnaires of
an embarrassing, and potentially offensive, nature and recommends the use of a
specialized methodology to make respondents more comfortable during this
process. METHODS: To establish guidelines for debriefing PROs of a sensitive na-
ture, subject feedback from previous ED questionnaire debriefing reports was ex-
amined. The subjects that expressed the most discomfort during the debriefing
process resided in India, Africa, and the Middle East. Additionally, older subjects
and subjects with lower levels of education were more likely to express reserva-
tions. For this study, we collaboratedwith translators from each of these regions to
determine a list of measures that can be taken to help ensure that subjects feel
comfortable enough to provide reliable feedback within the interview setting.
RESULTS: The goal of any cognitive debriefing session is to adequately test the
translated questionnaire while maintaining the cultural sensitivities of the target
country. Recommended considerations include: assigning an interviewer of the
same sex as the subject, performing a specialized training session with interview-
ers that reviews subjects’ boundaries and strategies for effective probing, sending
subjects an introductory note that emphasizes confidentiality prior to the inter-
view, conducting interviews via telephone rather than in-person, and debriefing
questionnaires via a web-based device. CONCLUSIONS: For some cultures, cogni-
tively debriefing PRO questionnaires of a sensitive nature places added burden on
respondents. Evidence suggests that additional considerations should be exercised
during debriefing to respect subjects’ cultural boundaries.
Infection – Clinical Outcomes Studies
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VACCINE-ASSOCIATED GUILLAIN-BARRE SYNDROME: A PHARMACOVIGILANCE
ANALYSIS OF DATA IN THE UNITED STATES’ VACCINE ADVERSE EVENT
REPORTING SYSTEM (1990-2009)
Ali AK
University of Florida, Gainesville, FL, USA
OBJECTIVES: To describe reporting rates and characteristics of vaccine-associated
GBS reports in the Vaccine Adverse Event Reporting System (VAERS) over a two-
decade period.METHODS:Adverse event reports submitted to VAERS from January
1990 to November 2009 are utilized to conduct a retrospective pharmacovigilance
analysis by calculating the proportional reporting ratios (PRR) and corresponding
95% confidence intervals (CI) for vaccine-GBS event pairs. RESULTS: One thousand
and 259 reports of vaccine-associated GBS are identified for 37 vaccines. Themean
age of patients experienced GBS after vaccination was 31 years; 51% of patients
were females. Majority of the reports were for influenza (FLU) (791) and hepatitis B
(HEP) virus vaccines (103). Reports for human papillomavirus quadrivalent (HPV4),
meningococcal conjugate (MNQ), and measles/mumps/rubella (MMR) virus vac-
cines accounted for 37, 36, and 34 reports, respectively. Death, disability and hos-
pitalization among the serious GBS outcomes were correspondingly reported in 36
(2.9%), 199 (15.8%), and 963 (76.4%) reports. Most of these outcomes were in FLU
reports. The average postvaccination GBS onset delay was 3.5 weeks; ranging from
2.3weeks for FLU to 8.1weeks forMNQ. About 79% and 12% of GBS reports included
A113V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
